Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into

Executive Summary

The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.

You may also be interested in...



Novartis Gets First-Mover Advantage With FDA Approval Of Cosentyx For Psoriasis

Secukinumab gets to market before competing IL-17 inhibitors from Lilly and AstraZeneca/Amgen are even filed for approval. Wall Street is expecting blockbuster sales for psoriasis agents that can improve upon the performance of TNF inhibitors.

Novartis’ Secukinumab Sails Through Advisory Panel, Bodes Well For IL-17 Class

Unanimous advisory committee vote positions Novartis’ secukinumab to beat Lilly and Amgen/AstraZeneca competitors to market; panel supportive of Novartis’ preferred dose, letting other dosing issues be further explored post-market.

Secukinumab Phase III Data Look Reassuring Ahead Of Advisory Committee Review

Efficacy results look solid in pair of Phase III trials published in NEJM, but some question whether a double dose adds enough to get approval. Investigators note prevalence of Candida infections in patients on the Novartis drug.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS054600

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel